BC Week In Review | May 5, 2017
Clinical News

Cantex starts Ph II glioblastoma trial of CX-02

Cantex Pharmaceuticals Inc. (Weston, Fla.) began a Phase II trial of CX-02 to treat recurrent glioblastoma. The open-label, U.S. trial will evaluate objective response rate (ORR) as the primary endpoint in about 20 patients receiving...
BC Week In Review | Jun 1, 2015
Clinical News

CX-01: Phase I data

An open-label, U.S. Phase I trial in 12 AML patients showed that induction chemotherapy consisting of cytarabine and idarubicin plus CX-01 as a continuous infusion for 7 days following a bolus led to morphologic complete...
Items per page:
1 - 2 of 2